You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The seven-gene test, ColonSentry, is designed to determine an individual's current risk for colorectal cancer relative to an average risk population.
Oncore and its partners will commercialize GeneNews' ColonSentry test in all countries outside the US and Canada under the five-year exclusive agreement
The company has struck a deal to market its tests, including ones based on its Aristotle early cancer detection platform, in collaboration with LifeX.
The companies have signed a deal under which each will make its tests available to the other's customer base.
The company had to halt and later restart billing for its cancer risk assessment tests as it transitioned to a new billing process.
The company attributed the revenue decline to ongoing changes in how it bills for its diagnostics.
The company attributed the decline in revenues to changes it is making in the billing process for its diagnostics.
GeneNews said that it has decided to make an initial draw down of $500,000 to help "fuel the company's momentum while minimizing dilution."
The decline reflects a drop off in sales of its ColonSentry colorectal cancer blood test and other diagnostics.
GeneNews has signed a binding agreement with multinational private equity firm Milost Global for up to $10 million in equity and debt financing.
The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.
According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.
The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.
In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.